- Home
- DTIL vs CLSD Comparison
DTIL vs CLSD Comparison
Compare DTIL & CLSD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTIL
- CLSD
- Stock Information
- Founded
- DTIL 2006
- CLSD 2011
- Country
- DTIL United States
- CLSD United States
- Employees
- DTIL N/A
- CLSD N/A
- Industry
- DTIL Biotechnology: Pharmaceutical Preparations
- CLSD Biotechnology: Pharmaceutical Preparations
- Sector
- DTIL Health Care
- CLSD Health Care
- Exchange
- DTIL Nasdaq
- CLSD Nasdaq
- Market Cap
- DTIL 51.6M
- CLSD 59.1M
- IPO Year
- DTIL 2019
- CLSD 2016
- Fundamental
- Price
- DTIL $4.49
- CLSD $0.87
- Analyst Decision
- DTIL Strong Buy
- CLSD Strong Buy
- Analyst Count
- DTIL 2
- CLSD 4
- Target Price
- DTIL $47.00
- CLSD $4.75
- AVG Volume (30 Days)
- DTIL 546.0K
- CLSD 179.1K
- Earning Date
- DTIL 07-31-2025
- CLSD 08-11-2025
- Dividend Yield
- DTIL N/A
- CLSD N/A
- EPS Growth
- DTIL N/A
- CLSD N/A
- EPS
- DTIL N/A
- CLSD N/A
- Revenue
- DTIL $51,141,000.00
- CLSD $3,764,000.00
- Revenue This Year
- DTIL N/A
- CLSD $60.52
- Revenue Next Year
- DTIL $30.20
- CLSD $88.28
- P/E Ratio
- DTIL N/A
- CLSD N/A
- Revenue Growth
- DTIL N/A
- CLSD N/A
- 52 Week Low
- DTIL $3.61
- CLSD $0.70
- 52 Week High
- DTIL $11.09
- CLSD $1.65
- Technical
- Relative Strength Index (RSI)
- DTIL 54.93
- CLSD 58.96
- Support Level
- DTIL $4.08
- CLSD $0.80
- Resistance Level
- DTIL $4.38
- CLSD $0.88
- Average True Range (ATR)
- DTIL 0.28
- CLSD 0.04
- MACD
- DTIL 0.05
- CLSD 0.01
- Stochastic Oscillator
- DTIL 85.26
- CLSD 84.82
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
About CLSD Clearside Biomedical Inc.
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing a proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.